John M Maris MD

Pediatric Hematology & Oncology•Philadelphia, PA

Professor, Pediatrics, Perelman School of Medicine

Join to View Full Profile

3401 Civic Center Blvd# ChildrenPhiladelphia, PA 19104
Phone+1 215-590-3535
Fax+1 215-590-3992

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1992 - 1995
Children's Hospital of PhiladelphiaResidency, Pediatrics, 1989 - 1992
Perelman School of Medicine at the University of PennsylvaniaClass of 1989

Certifications & Licensure

NJ State Medical License 1993 - Present
PA State Medical License 1991 - 2026
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Philadelphia Magazine Castle Connolly, 2005-2006, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Elected Member The American Society for Clinical Investigation, 2007
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
ACTIVE_NOT_RECRUITING
PHASE3
N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation Start of enrollment: 2004 Mar 01
Completed
Phase 1
N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2003 Aug 01
Completed
Phase 1
N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma Start of enrollment: 2005 Sep 01
Completed
Phase 2
131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2005 Apr 01
Completed
Phase 2
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Start of enrollment: 2005 Dec 01
Completed
Phase 1
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions Start of enrollment: 2006 Dec 11
Completed
N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma Start of enrollment: 2006 Dec 01
Completed
Phase 1
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
AVAILABLE
Biomarkers in Young Patients With Neuroblastoma Start of enrollment: 2010 Jul 01
Completed
Next Generation Personalized Neuroblastoma Therapy
TERMINATED
PHASE1
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Start of enrollment: 2016 Dec 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study.
Esther R Berko, Arlene Naranjo, Alexander A Daniels, Samantha N McNulty, Kateryna Krytska
Journal of Clinical Oncology. 2025-03-04
ImmunoTar-integrative prioritization of cell surface targets for cancer immunotherapy.
Rawan Shraim, Brian Mooney, Karina L Conkrite, Amber K Hamilton, Gregg B Morin
Bioinformatics. 2025-03-04
1 citations
The Open Pediatric Cancer Project.
Zhuangzhuang Geng, Eric Wafula, Ryan J Corbett, Yuanchao Zhang, Run Jin
Biorxiv. 2025-03-01

Press Mentions

Children’s Hospital of Philadelphia Researchers Reveal New Hope for Chemotherapy-Resistant Neuroblastoma PatientsAugust 13th, 2024
Collaboration Aims to ‘Truly Accelerate Better Treatments’ for Pediatric CancersMay 9th, 2023
Perelman School of Medicine Awards & Accolades: December 2022January 24th, 2023
Join now to see all

Grant Support

Discovering and Exploiting Mechanisms of Neuroblastoma Therapy ResistanceCHILDREN'S HOSP OF PHILADELPHIA2017–2029
Personalized neuroblastoma vaccinesCHILDREN'S HOSP OF PHILADELPHIA2023–2028
Personalized neuroblastoma vaccinesCHILDREN'S HOSP OF PHILADELPHIA2023–2028
Personalized neoantigen vaccines using nucleoside-modified mRNA-lipid nanoparticlesCHILDREN'S HOSP OF PHILADELPHIA2023–2028
Personalized neuroblastoma vaccinesCHILDREN'S HOSP OF PHILADELPHIA2023–2028
Personalized neuroblastoma vaccinesCHILDREN'S HOSP OF PHILADELPHIA2023–2028
Personalized neoantigen vaccines using nucleoside-modified mRNA-lipid nanoparticlesCHILDREN'S HOSP OF PHILADELPHIA2023–2028
Personalized neoantigen vaccines using nucleoside-modified mRNA-lipid nanoparticlesCHILDREN'S HOSP OF PHILADELPHIA2023–2028
Personalized neoantigen vaccines using nucleoside-modified mRNA-lipid nanoparticlesCHILDREN'S HOSP OF PHILADELPHIA2023–2028
NextGen - CHOPCHILDREN'S HOSP OF PHILADELPHIA2024–2025
NextGen - CHOPCHILDREN'S HOSP OF PHILADELPHIA2024–2025
NextGen - CHOPCHILDREN'S HOSP OF PHILADELPHIA2024–2025
NextGen - CHOPCHILDREN'S HOSP OF PHILADELPHIA2024–2025
NextGen - CHOPCHILDREN'S HOSP OF PHILADELPHIA2022–2025
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesCHILDREN'S HOSP OF PHILADELPHIA2017–2025
The Genetic Basis Of Neuroblastoma TumorigenesisNational Cancer Institute2008–2012
Cancer Center Research Training ProgramNational Cancer Institute2008–2011
Significance Of Genetic Alterations In NeuroblastomaNational Cancer Institute2004–2006
Isolation Of The Neuroblastoma Predisposition GeneNational Cancer Institute2004–2006
Chp677: I-MIBG Therapy For Refractory Neuroblastoma: Phase II StudyNational Center For Research Resources2004
Significance Of Genetic Alterations In NeuroblastomaNational Cancer Institute2002–2003
Isolation Of The Neuroblastoma Predisposition GeneNational Cancer Institute1998–2003
Isolation Of The Neuroblastoma Predisposition GeneNational Center For Research Resources2000–2002
Buthionine Suifoximine In Combination With Melphalan For Pediatric NeuroblastomaNational Center For Research Resources1998–2002
Significance Of Allelic Deletions In NeuroblastomaNational Cancer Institute1998–1999